Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study

Ninan, Jem; Nguyen, Anh–Minh; Cole, Antonia; Rischmueller, Maureen; Dodd, Thomas J.; Roberts‐Thomson, Peter; Hill, Catherine

doi:10.3899/jrheum.101254

Cited by 46 publications

(26 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with GCA were also found to have increased rates of mild-moderate infections diagnosed and treated at an outpatient visit and acute upper respiratory tract infections (data not shown). These data underline the risks for infection among patients with GCA, and the concerns for infection-related mortality (24).…”

Section: Discussionmentioning

confidence: 71%

Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study

et al. 2016

View full text Add to dashboard Cite

Objective.To compare the rate of occurrence of comorbidities, including severe infections, in a population-based cohort of patients with biopsy-proven giant cell arteritis (GCA) with a reference population in Southern Sweden.Methods.The study included a population-based cohort of biopsy-proven GCA cases diagnosed between 1998 and 2010 from the Skåne region in Southern Sweden (population: 1.2 million). For each patient, 4 reference subjects were identified from the general population and matched for age, sex, area of residence, and date of diagnosis of GCA. Using the Skåne Healthcare Register, comorbidities and severe infections (requiring hospitalization) diagnosed after GCA onset were identified. The rate of the first occurrence of each comorbidity was the result of dividing the number of subjects with a given comorbidity by the person-years of followup. The rate ratio (RR; GCA:reference population) was also calculated.Results.There were 768 patients (571 women) with GCA and 3066 reference persons included in the study. The RR were significantly elevated for osteoporosis (2.81, 95% CI 2.33–3.37), followed by venous thromboembolic diseases (2.36, 95% CI 1.61–3.40), severe infections (1.85, 95% CI 1.57–2.18), thyroid diseases (1.55, 95% CI 1.25–1.91), cerebrovascular accidents (1.40, 95% CI 1.12–1.74), and diabetes mellitus (1.29, 95% CI 1.05–1.56). The RR for ischemic heart disease was elevated, but did not reach statistical significance (1.20, 95% CI 1.00–1.44).Conclusion.Patients with GCA have higher rates of selected comorbidities, including severe infections, compared with a reference population. Several of these comorbidities may be related to treatment with glucocorticosteroids, emphasizing the unmet need to find alternative treatments for GCA.

show abstract

Section: Discussionmentioning

confidence: 71%

Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, the mortality was higher early in the disease course, especially in patients younger than 70 years at time of diagnosis. Most previous studies showed no increase in mortality compared with the general population,13 including studies of patients with biopsy-proven GCA from Gothenburg14 and Australia 17. Increased mortality was previously reported in studies from Denmark16 and northern Sweden,30 in the latter, mainly due to cardiovascular disease.…”

Section: Discussionmentioning

confidence: 82%

Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, despite the serious consequences of GCA and the required high‐dose corticosteroid therapy, the mortality rate is generally reported to be equal to the general population . A recent study of mortality in South Australian biopsy‐proven GCA patients reported no significant differences in mortality between GCA patients and the general South Australian population, after adjusting for age and gender .…”

Section: Discussionmentioning

confidence: 99%